Volume 15, Number 12—December 2009
Research
Cost-effectiveness Analysis of Hospital Infection Control Response to an Epidemic Respiratory Virus Threat
Table 2
Variable | Description | Base case | Sensitivity analysis |
---|---|---|---|
Exposure | No. persons exposed in 1 day in hospital per index case (nonlinear) | 15 (average for 2 days) 6 (average for 5 days) | 2–30 |
Secondary attack rate | No. persons exposed/infected | 30% Spanish influenza 10% SARS 30% pandemic (H1N1) 2009 | 10–100% |
Incubation period | Time to symptoms | Spanish influenza: 2 days SARS: 4 day Pandemic (H1N1) 2009: 3 days | 1–7 |
Infectious period preclinical | Incubation–latent | Spanish influenza: 1 day SARS: 0 day Pandemic (H1N1) 2009: 1 day | 1–3 |
% Clinical versus asymptomatic | Spanish influenza: 95% SARS: 100% Pandemic (H1N1) 2009: 95% | 70–100% | |
% Atypical (missed) | Spanish influenza: 5% SARS: 20% Pandemic (H1N1) 2009: 5% | 0–50% | |
% Complication | 10× mortality rate | ||
Infective atypical | Infective | 4 days | 1–7 |
Case-fatality rate | % death | Spanish influenza: 5% SARS: 10% Pandemic (H1N1) 2009: 4% | |
Isolation failure | Transmission despite PPE/isolation | 5% | 0–10% |
Exposure reduction | % reduction in exposure rate | Alert Green 50% Alert Yellow 80% Alert Orange 90% | 0–100% |
Cost based on alert policy, direct and indirect | Once Daily recurring | Activation: US$110,000 Green: US$4,000 Yellow: US$76,000 Orange: US$100,000 | |
Cost by type of treatment, based on actual financial charges | Isolation Treatment antiviral/day Uncomplicated influenza Complicated influenza Respiratory failure with mechanical ventilation | US$230 US$25 Mean: US$600, Median: US$420 Mean: US$1800, Median: US$220 Mean: US$5,500, Median:US$4,660 |
*SARS, severe acute respiratory syndrome; PPE, personal protective equipment.
Page created: December 09, 2010
Page updated: December 09, 2010
Page reviewed: December 09, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.